Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.69 · Revenue $31.40M · 2 analysts
Est. EPS $-0.69 · Revenue $35.03M · 2 analysts
Est. EPS $-3.09 · Revenue $125.97M · 2 analysts
Est. EPS $-0.81 · Revenue $29.70M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $119.5M | +5.1% | +13.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-81.7M | +36.2% | +5.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +39.1% | +15.4% | -3.3% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -55.8% | +44.0% | +18.4% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -68.3% | +39.3% | +16.5% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-47.1M | +59.8% | +24.5% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -39.4% | +61.7% | +33.5% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 79.8% | -89.4% | +19.2% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.67x | +17.2% | -17.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $264.5M | -4.1% | -2.8% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -5.37 vs -4.45 | -20.6% | -0.97 vs -0.72 | -35.3% |
| Revenue Surprise | $119.5M vs $117.2M | +1.9% | $31.6M vs $29.0M | +9.2% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Trigg Leslie | director, officer: Chair and CEO | Common Stock | D | 3,437 | $4.39 |
| Aug 17, 2026 | Brottem John L. | officer: General Counsel | Common Stock | D | 2,632 | $4.39 |
| Aug 17, 2026 | Gaeta Renee | officer: Chief Financial Officer | Common Stock | D | 4,543 | $4.39 |
| Jun 26, 2026 | Brottem John L. | officer: General Counsel | Common Stock | A | 59,830 | — |
| Jun 26, 2026 | Gaeta Renee | officer: Chief Financial Officer | Common Stock | A | 71,630 | — |
Operator: Good day, and thank you for standing by. Welcome to the Outset Medical Q2 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Tina Jacobson, Investor Relations. Please go ahead. Unknown Executive: Good afternoon, everyone, and welcome to Outset Medical's Second Quarter 2026 Earnings Call. Today's speakers are Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer. The company issued a news release after the close of the market today, which can be found in the investor section of outsetmedical.com. This call is being recorded and will be archived there as well. All forward-looking statements made during today's call are intended to be protected under the Private Securities Litigation Reform Act of 1995. Outset assumes no obligation to update these statements. For a list and description of the risks and uncertainties associated with the business, please refer to Outset's public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. With that, I'll open the call to Leslie Trigg. Leslie? Leslie Trigg: Good afternoon, everyone, and thank you for joining us. The second quarter reflected steady execution across revenue, gross margin, operating expense discipline, and cash management. We continue to make meaningful commercial progress while advancing our mission to improve dialysis patient outcomes at a lower cost and with less complexity. We are confident that the impact of that progress will become increasingly evident over time. I'll begin today with financial performance in the second quarter. Revenue of $31.6 million was up 1% year-over-year and up 14% sequentially. Our ongoing margin expansion program delivered a non-GAAP gross margin of 42%, a significant improvement compared to last year. With the solid second quarter results, we are reiterating full year 2026 revenue guidance of $125 million to $130 million. During the second quarter, we completed our highest number of successful new site implementations in several years. At one system with several sites in Texas, our clinical excellence team trained over 100 nurses who, in turn, supported 956 treatments in their first 60 days. Other successful implementations were completed at a new top 10 health system customer for Outset, as well as at hospitals that are part of large regional health systems and post-acute care facilities. What stands out most is what happened after the initial go-live implementation. Outset has established a clinical excellence team focused on helping our customers optimize the clinical, financial, and operational value of their Tablo in-sourcing programs over the long term. Each hospital customer is paired with a clinical excellence team member who works closely with them to identify the outcomes that matter most to their organization and then …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Leslie L. Trigg | President, Chief Executive Officer & Chairman | USD 1,057,628 | Female | 1971 | Active |
John L. Brottem | General Counsel & Secretary | USD 566,087 | Male | 1974 | Active |
Renee Gaeta | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | USD 336,048 | Female | 1981 | Active |
Brett Fogg | Senior Vice President of R&D & Operations | — | Male | — | Active |
Derick Elliott | Executive Vice President of Commercial | — | Male | — | Active |
Jaime Pulido | Senior Vice President of Finance | — | Male | — | Active |
Michael Aragon | Chief Medical Officer | — | — | — | Active |
Brittni McGill | Chief Nursing Officer | — | Female | — | Active |
Amelia Merrill | Vice President of People Operations & Culture | — | — | — | Active |
Dinamarie Stefani | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — | — | Active |
Outset Medical (OM) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript
Outset Medical NASDAQ: OM reported second-quarter 2026 revenue of $31.6 million, up 1% from a year earlier and 14% sequentially, as the dialysis technology company cited commercial progress, improving margins and a new $40 million refresh agreement with HCA Healthcare.
Outset Medical, Inc. (OM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to a loss of $0.84 per share a year ago.
SAN JOSE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the second quarter ended June 30, 2026.
